Immune checkpoint inhibitors: recent progress and potential biomarkers

Article Properties
Abstract
Login
Cite
Darvin, Pramod, et al. “Immune Checkpoint Inhibitors: Recent Progress and Potential Biomarkers”. Experimental &Amp; Molecular Medicine, vol. 50, no. 12, 2018, pp. 1-11, https://doi.org/10.1038/s12276-018-0191-1.
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018). Immune checkpoint inhibitors: recent progress and potential biomarkers. Experimental &Amp; Molecular Medicine, 50(12), 1-11. https://doi.org/10.1038/s12276-018-0191-1
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Experimental & Molecular Medicine. 2018;50(12):1-11.
Journal Categories
Medicine
Medicine
Medicine (General)
Science
Biology (General)
Science
Chemistry
Organic chemistry
Biochemistry
Refrences
Login
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)55
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens31
Medicine: Internal medicine12
Science: Biology (General)7
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy7
The category Medicine: Medicine (General) 55 is the most frequently represented among the references in this article. It primarily includes studies from New England Journal of Medicine The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Login
Citations Analysis
Category Category Repetition
Medicine: Medicine (General)536
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens393
Science: Biology (General)201
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy166
Medicine: Therapeutics. Pharmacology150
The first research to cite this article was titled Immune checkpoint inhibitors in the driver’s seat: Evaluating the evolving evidence in the treatment of extensive-stage small-cell lung cancer and was published in 2019. The most recent citation comes from a 2024 study titled Immune checkpoint inhibitors in the driver’s seat: Evaluating the evolving evidence in the treatment of extensive-stage small-cell lung cancer . This article reached its peak citation in 2021 , with 319 citations.It has been cited in 510 different journals, 28% of which are open access. Among related journals, the Cancers cited this research the most, with 77 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year